2019 ASCO Annual Meeting – poster
June 3, 2019
New data from Oncopeptides phase 1/2 O-12-M1 trial evaluating melflufen in RRMM presented at 2019 ASCO annual meeting by Professor Paul G. Richardson.
-
Change Region
-
Global
-
United States
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you to the website of our US operations, Oncopeptides Inc. at oncopeptides-us.com
-
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Change Language
-
-
ONCO4.76 SEK+27.6%1 SEK
-
-
Change Region
-
Global
-
United States
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you to the website of our US operations, Oncopeptides Inc. at oncopeptides-us.com
-
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Change Language
-
-
ONCO4.76 SEK+27.6%1 SEK
-